These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 3821919)
1. Therapeutic application of radiolabeled monoclonal antibody UJ13A in children with disseminated neuroblastoma. Lashford L; Jones D; Pritchard J; Gordon I; Breatnach F; Kemshead JT NCI Monogr; 1987; (3):53-7. PubMed ID: 3821919 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic application of radiolabelled monoclonal antibody UJ13A in children with disseminated neuroblastoma--a phase 1 study. Kemshead JT; Goldman A; Jones D; Pritchard J; Malpas JS; Gordon I; Malone JF; Hurley GD; Breatnach F Prog Clin Biol Res; 1985; 175():533-44. PubMed ID: 4039447 [No Abstract] [Full Text] [Related]
3. Tumor spheroid model for the biologically targeted radiotherapy of neuroblastoma micrometastases. Walker KA; Mairs R; Murray T; Hilditch TE; Wheldon TE; Gregor A; Hann IM Cancer Res; 1990 Feb; 50(3 Suppl):1000s-1002s. PubMed ID: 2297711 [TBL] [Abstract][Full Text] [Related]
4. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Brown MT; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Reiman R; Felsberg GJ; Tien RD; Bigner SH; Zalutsky MR; Zhao XG; Wikstrand CJ; Pegram CN; Herndon JE; Vick NA; Paleologos N; Fredericks RK; Schold SC; Bigner DD Clin Cancer Res; 1996 Jun; 2(6):963-72. PubMed ID: 9816257 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma. Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989 [TBL] [Abstract][Full Text] [Related]
6. Nuclear medicine therapy of neuroblastoma. Hoefnagel CA Q J Nucl Med; 1999 Dec; 43(4):336-43. PubMed ID: 10731784 [TBL] [Abstract][Full Text] [Related]
7. Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma. Dauer LT; St Germain J; Williamson MJ; Zanzonico P; Modak S; Cheung NK; Divgi C Health Phys; 2007 Jan; 92(1):33-9. PubMed ID: 17164597 [TBL] [Abstract][Full Text] [Related]
9. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891 [TBL] [Abstract][Full Text] [Related]
10. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model. Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357 [TBL] [Abstract][Full Text] [Related]
11. Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies. DeNardo DA; DeNardo GL; Yuan A; Shen S; DeNardo SJ; Macey DJ; Lamborn KR; Mahe M; Groch MW; Erwin WD J Nucl Med; 1996 Dec; 37(12):1970-5. PubMed ID: 8970516 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378 [TBL] [Abstract][Full Text] [Related]
13. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. Matthay KK; Panina C; Huberty J; Price D; Glidden DV; Tang HR; Hawkins RA; Veatch J; Hasegawa B J Nucl Med; 2001 Nov; 42(11):1713-21. PubMed ID: 11696644 [TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038 [TBL] [Abstract][Full Text] [Related]
15. Comparison of systemic radiotherapy with I-131-labeled monoclonal antibody BW575/9 to external beam radiotherapy in human neuroblastoma xenografts. Sautter-Bihl ML; Wessely R; Bihl H Strahlenther Onkol; 1993 Oct; 169(10):595-600. PubMed ID: 8235984 [TBL] [Abstract][Full Text] [Related]
16. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726 [TBL] [Abstract][Full Text] [Related]
20. [131I]MIBG as a first line treatment in advanced neuroblastoma. Hoefnagel CA; De Kraker J; Valdés Olmos RA; Voûte PA Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):61-4. PubMed ID: 9002752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]